[1]林桐榆,于世英,焦长顺.恶性肿瘤靶向治疗[M].北京:人民卫生出版社,2016:25-33.
[2]Brasó-Maristany F,et al. Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response. Nat Commun. 2024 Jul 11;15(1):5826.
[3]Barbara Pistilli et al. Efficacy, safety and biomarker analysis of ICARUS-BREAST01: a phase 2 Study of Patritumab Deruxtecan (HER3-DXd) in patients (pts) with HR+/HER2- advanced breast cancer (ABC). 2024 ESMO abstr 340O.